Biotechnology Chinese biotech BeiGene on Friday said that the China National Medical Products Administration (NMPA) has granted conditional approval to its anti-PD-1 antibody, tislelizumab, for the treatment of adult patients with advanced unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, including: 14 March 2022